Beyondspring (NASDAQ:BYSI) Upgraded to Buy at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Beyondspring (NASDAQ:BYSI) from a hold rating to a buy rating in a report published on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $23.00 target price on the stock.

According to Zacks, “BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company’s lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. “

Several other analysts have also recently weighed in on BYSI. Maxim Group restated a buy rating and set a $58.00 price objective on shares of Brinker International in a research report on Tuesday, April 30th. HC Wainwright restated a buy rating and set a $60.00 price objective on shares of Beyondspring in a research report on Wednesday.

Shares of NASDAQ:BYSI opened at $20.70 on Wednesday. The firm has a fifty day moving average price of $19.20. Beyondspring has a one year low of $13.06 and a one year high of $26.98.

Beyondspring (NASDAQ:BYSI) last posted its quarterly earnings data on Wednesday, July 10th. The company reported ($0.32) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.31. On average, equities research analysts anticipate that Beyondspring will post -1.15 earnings per share for the current year.

Beyondspring Company Profile

BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.

Featured Story: Net Income

Get a free copy of the Zacks research report on Beyondspring (BYSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Preformed Line Products  Stock Passes Above 200-Day Moving Average of $0.00
Preformed Line Products Stock Passes Above 200-Day Moving Average of $0.00
Aristocrat Leisure  Share Price Crosses Above Two Hundred Day Moving Average of $0.00
Aristocrat Leisure Share Price Crosses Above Two Hundred Day Moving Average of $0.00
Mullen Group  Stock Price Passes Below 50 Day Moving Average of $7.26
Mullen Group Stock Price Passes Below 50 Day Moving Average of $7.26
Veolia Environnement  Share Price Passes Below Fifty Day Moving Average of $21.59
Veolia Environnement Share Price Passes Below Fifty Day Moving Average of $21.59
McBride  Stock Price Passes Below 50-Day Moving Average of $78.98
McBride Stock Price Passes Below 50-Day Moving Average of $78.98
CounterPath  Stock Price Passes Above 200 Day Moving Average of $0.00
CounterPath Stock Price Passes Above 200 Day Moving Average of $0.00


 
© 2006-2019 Zolmax.